Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases.
D Sofia Villacis-NunezChristina A RostadKelly Rouster-StevensArezou KhosroshahiShanmuganathan ChandrakasanSampath PrahaladPublished in: Pediatric rheumatology online journal (2021)
Medium/high-dose corticosteroid, mycophenolate and rituximab use, and severe immunosuppression were risk factors for hospitalization. Fever, dyspnea, chest pain, and rash were high-risk symptoms for hospitalization. Rheumatic disease activity and flare could contribute to the need for hospitalization.
Keyphrases
- disease activity
- rheumatoid arthritis
- high dose
- systemic lupus erythematosus
- rheumatoid arthritis patients
- coronavirus disease
- ankylosing spondylitis
- sars cov
- juvenile idiopathic arthritis
- low dose
- diffuse large b cell lymphoma
- early onset
- metabolic syndrome
- hodgkin lymphoma
- adipose tissue
- depressive symptoms
- chronic lymphocytic leukemia
- respiratory syndrome coronavirus
- drug induced
- weight loss
- glycemic control